<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34739847</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2213-6711</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Stem cell reports</Title>
          <ISOAbbreviation>Stem Cell Reports</ISOAbbreviation>
        </Journal>
        <ArticleTitle>PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs.</ArticleTitle>
        <Pagination>
          <StartPage>2958</StartPage>
          <EndPage>2972</EndPage>
          <MedlinePgn>2958-2972</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stemcr.2021.10.004</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2213-6711(21)00539-7</ELocationID>
        <Abstract>
          <AbstractText>Proprotein convertase subtilisin kexin type 9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) cholesterol metabolism and the target of lipid-lowering drugs. PCSK9 is mainly expressed in hepatocytes. Here, we show that PCSK9 is highly expressed in undifferentiated human induced pluripotent stem cells (hiPSCs). PCSK9 inhibition in hiPSCs with the use of short hairpin RNA (shRNA), CRISPR/cas9-mediated knockout, or endogenous PCSK9 loss-of-function mutation R104C/V114A unveiled its new role as a potential cell cycle regulator through the NODAL signaling pathway. In fact, PCSK9 inhibition leads to a decrease of SMAD2 phosphorylation and hiPSCs proliferation. Conversely, PCSK9 overexpression stimulates hiPSCs proliferation. PCSK9 can interfere with the NODAL pathway by regulating the expression of its endogenous inhibitor DACT2, which is involved in transforming growth factor (TGF) β-R1 lysosomal degradation. Using different PCSK9 constructs, we show that PCSK9 interacts with DACT2 through its Cys-His-rich domain (CHRD) domain. Altogether these data highlight a new role of PCSK9 in cellular proliferation and development.</AbstractText>
          <CopyrightInformation>Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Roudaut</LastName>
            <ForeName>Meryl</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France; HCS Pharma, Lille, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Idriss</LastName>
            <ForeName>Salam</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France; ER045 - Laboratory of Stem Cells: Maintenance, Differentiation and Pathology, Biology Department, Faculty of Sciences, Lebanese University, Beirut, Lebanon.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Caillaud</LastName>
            <ForeName>Amandine</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Girardeau</LastName>
            <ForeName>Aurore</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rimbert</LastName>
            <ForeName>Antoine</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Champon</LastName>
            <ForeName>Benoite</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>David</LastName>
            <ForeName>Amandine</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lévêque</LastName>
            <ForeName>Antoine</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arnaud</LastName>
            <ForeName>Lucie</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pichelin</LastName>
            <ForeName>Matthieu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France; Université de Nantes, CHU Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Prieur</LastName>
            <ForeName>Xavier</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Prat</LastName>
            <ForeName>Annik</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>University of Montreal, Montreal, QC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Seidah</LastName>
            <ForeName>Nabil G</ForeName>
            <Initials>NG</Initials>
            <AffiliationInfo>
              <Affiliation>University of Montreal, Montreal, QC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zibara</LastName>
            <ForeName>Kazem</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>ER045 - Laboratory of Stem Cells: Maintenance, Differentiation and Pathology, Biology Department, Faculty of Sciences, Lebanese University, Beirut, Lebanon.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Le May</LastName>
            <ForeName>Cedric</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cariou</LastName>
            <ForeName>Bertrand</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France; Université de Nantes, CHU Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France. Electronic address: bertrand.cariou@univ-nantes.fr.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Si-Tayeb</LastName>
            <ForeName>Karim</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Université de Nantes, CNRS, INSERM, l'institut du thorax, 44000 Nantes, France. Electronic address: karim.si-tayeb@univ-nantes.fr.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Stem Cell Reports</MedlineTA>
        <NlmUniqueID>101611300</NlmUniqueID>
        <ISSNLinking>2213-6711</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C478653">DACT2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D055457">Nodal Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018125">Receptors, Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051899">Smad2 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000073658" MajorTopicYN="N">Loss of Function Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055457" MajorTopicYN="N">Nodal Protein</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071449" MajorTopicYN="N">Proprotein Convertase 9</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018125" MajorTopicYN="N">Receptors, Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051899" MajorTopicYN="N">Smad2 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">DACT2</Keyword>
        <Keyword MajorTopicYN="Y">NODAL</Keyword>
        <Keyword MajorTopicYN="Y">PCSK9</Keyword>
        <Keyword MajorTopicYN="Y">SMAD2</Keyword>
        <Keyword MajorTopicYN="Y">TGFβR1</Keyword>
        <Keyword MajorTopicYN="Y">hiPSC</Keyword>
        <Keyword MajorTopicYN="Y">proliferation</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>5</Day>
          <Hour>20</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34739847</ArticleId>
        <ArticleId IdType="pmc">PMC8693623</ArticleId>
        <ArticleId IdType="doi">10.1016/j.stemcr.2021.10.004</ArticleId>
        <ArticleId IdType="pii">S2213-6711(21)00539-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abifadel M., Varret M., Rabès J.P., Allard D., Ouguerram K., Devillers M., Cruaud C., Benjannet S., Wickham L., Erlichje D., et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 2003;34:154–156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12730697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almeida C.R., Ferreira B.H., Duarte I.F. Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy. Signal Transduct. Target Ther. 2021;6:111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7936974</ArticleId>
            <ArticleId IdType="pubmed">33677469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>An D., Wei X., Li H., Gu H., Huang T., Zhao G., Liu B., Wang W., Chen L., Ma W., et al.  Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics. Sci. Rep. 2015;5:17559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4686913</ArticleId>
            <ArticleId IdType="pubmed">26691006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Assou S., Le Carrour T., Tondeur S., Ström S., Gabelle A., Marty S., Nadal L., Pantesco V., Réme T., Hugnot J.-P., et al.  A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells. 2007;25:961–973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1906587</ArticleId>
            <ArticleId IdType="pubmed">17204602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benjannet S., Rhainds D., Essalmani R., Mayne J., Wickham L., Jin W., Asselin M.-C., Hamelin J., Varret M., Allard D., et al.  NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 2004;279:48865–48875.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15358785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calloni R., Cordero E.A.A., Henriques J.A.P., Bonatto D. Reviewing and updating the major molecular markers for stem cells. Stem Cells Dev. 2013;22:1455–1476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3629778</ArticleId>
            <ArticleId IdType="pubmed">23336433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cariou B., Ouguerram K., Zaïr Y., Guerois R., Langhi C., Kourimate S., Benoit I., Le May C., Gayet C., Belabbas K., et al.  PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler. Thromb. Vasc. Biol. 2009;29:2191–2197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19762784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cariou B., Si-Tayeb K., Le May C. Role of PCSK9 beyond liver involvement. Curr. Opin. Lipidol. 2015;26:155–161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25887680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Catapano A.L., Pirillo A., Norata G.D. New pharmacological approaches to target PCSK9. Curr. Atheroscler. Rep. 2020;22:1–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Cheyette B.N.R., Waxman J.S., Miller J.R., Takemaru K.I., Sheldahl L.C., Khlebtsova N., Fox E.P., Earnest T., Moon R.T. Dapper, a Dishevelled-associated antagonist of β-catenin and JNK signaling, is required for notochord formation. Dev. Cell. 2002;2:449–461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11970895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chng Z., Teo A., Pedersen R.A., Vallier L. SIP1 mediates cell-fate decisions between neuroectoderm and mesendoderm in human pluripotent stem cells. Cell Stem Cell. 2010;6:59–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20074535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 2006;354:1264–1272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16554528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ference B.A., Robinson J.G., Brook R.D., Catapano A.L., Chapman M.J., Neff D.R., Voros S., Giugliano R.P., Davey Smith G., Fazio S., et al.  Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N. Engl. J. Med. 2016;375:2144–2153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27959767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonsar N., Coughlin A., Clay-Wright J.A., Borg B.R., Kindt L.M., Liang J.O. Temporal and spatial requirements for Nodal-induced anterior mesendoderm and mesoderm in anterior neurulation. Genesis. 2016;54:3–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5515471</ArticleId>
            <ArticleId IdType="pubmed">26528772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hockemeyer D., Wang H., Kiani S., Lai C.S., Gao Q., Cassady J.P., Cost G.J., Zhang L., Santiago Y., Miller J.C., et al.  Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 2011;29:731–734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3152587</ArticleId>
            <ArticleId IdType="pubmed">21738127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J., Li L., Lian J., Schauer S., Vesely P.W., Kratky D., Hoefler G., Lehner R. Tumor-induced hyperlipidemia contributes to tumor growth. Cell Rep. 2016;15:336–348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4984953</ArticleId>
            <ArticleId IdType="pubmed">27050512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang T., David L., Mendoza V., Yang Y., Villarreal M., De K., Sun L., Fang X., López-Casillas F., Wrana J.L., et al.  TGF-β signalling is mediated by two autonomously functioning TβRI:TβRII pairs. EMBO J. 2011;30:1263–1276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3094126</ArticleId>
            <ArticleId IdType="pubmed">21423151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>James D., Levine A.J., Besser D., Hemmati-Brivanlou A. TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development. 2005;132:1273–1282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15703277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X., Bao X., Hu M., Chang H., Jiao M., Cheng J., Xie L., Huang Q., Li F., Li C.-Y. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588:693–698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7770056</ArticleId>
            <ArticleId IdType="pubmed">33177715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maxwell K.N., Breslow J.L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. U S A. 2004;101:7100–7105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC406472</ArticleId>
            <ArticleId IdType="pubmed">15118091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mi H., Ebert D., Muruganujan A., Mills C., Albou L.-P., Mushayamaha T., Thomas P.D. PANTHER version 16: a revised family classification, tree-based classification tool, enhancer regions and extensive API. Nucleic Acids Res. 2021;49:D394–D403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7778891</ArticleId>
            <ArticleId IdType="pubmed">33290554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Musunuru K., Chadwick A.C., Mizoguchi T., Garcia S.P., DeNizio J.E., Reiss C.W., Wang K., Iyer S., Dutta C., Clendaniel V., et al.  In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593:429–434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34012082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nassoury N., Blasiole D.A., Tebon Oler A., Benjannet S., Hamelin J., Poupon V., McPherson P.S., Attie A.D., Prat A., Seidah N.G. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic. 2007;8:718–732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17461796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pauklin S., Vallier L. Activin/Nodal signalling in stem cells. Development. 2015;142:607–619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25670788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poirier S., Mayer G., Poupon V., McPherson P.S., Desjardins R., Ly K., Asselin M.C., Dy R., Duclos F.J., Witmer M., et al.  Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation. Evidence for an intracellular route. J. Biol. Chem. 2009;284:28856–28864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2781431</ArticleId>
            <ArticleId IdType="pubmed">19635789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Preiss D., Tobert J.A., Hovingh G.K., Reith C. Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar. J. Am. Coll. Cardiol. 2020;75:1945–1955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32327106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabadán M.A., Herrera A., Fanlo L., Usieto S., Carmona-Fontaine C., Barriga E.H., Mayor R., Pons S., Martí E. Delamination of neural crest cells requires transient and reversible Wnt inhibition mediated by Dact1/2. Development. 2016;143:2194–2205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4920176</ArticleId>
            <ArticleId IdType="pubmed">27122165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rashid S., Curtis D.E., Garuti R., Anderson N.H., Bashmakov Y., Ho Y.K., Hammer R.E., Moon Y.A., Horton J.D. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. U S A. 2005;102:5374–5379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC556275</ArticleId>
            <ArticleId IdType="pubmed">15805190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Bélanger Jasmin S., Stifani S., Basak A., Prat A., Chrétien M., Jasmin S.B., et al.  The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. 2003;100:928–933.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC298703</ArticleId>
            <ArticleId IdType="pubmed">12552133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seidah N.G., Abifadel M., Prost S., Boileau C., Prat A. The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin/Kexin 9. Pharmacol. Rev. 2017;69:33–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27920219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Si-Tayeb K., Noto F.K., Sepac A., Sedlic F., Bosnjak Z.J., Lough J.W., Duncan S.A. Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC Dev. Biol. 2010;10:81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2923111</ArticleId>
            <ArticleId IdType="pubmed">20682060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Si-Tayeb K., Idriss S., Champon B., Caillaud A., Pichelin M., Arnaud L., Lemarchand P., Le May C., Zibara K., Cariou B. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia. Dis. Models Mech. 2016;9:81–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4728336</ArticleId>
            <ArticleId IdType="pubmed">26586530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stoekenbroek R.M., Lambert G., Cariou B., Hovingh G.K. Inhibiting PCSK9 - biology beyond LDL control. Nat. Rev. Endocrinol. 2018;15:52–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30367179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su Y., Zhang L., Gao X., Meng F., Wen J., Zhou H., Meng A., Chen Y. The evolutionally conserved activity of Dapper2 in antagonizing TGF-ß signaling. FASEB J. 2007;21:682–690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17197390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X., Essalmani R., Day R., Khatib A.M., Seidah N.G., Prat A. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Neoplasia. 2012;14:1122–1131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3540939</ArticleId>
            <ArticleId IdType="pubmed">23308045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topczewska J.M., Postovit L.M., Margaryan N.V., Sam A., Hess A.R., Wheaton W.W., Nickoloff B.J., Topczewski J., Hendrix M.J.C. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat. Med. 2006;12:925–932.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16892036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsuneyoshi N., Sumi T., Onda H., Nojima H., Nakatsuji N., Suemori H. PRDM14 suppresses expression of differentiation marker genes in human embryonic stem cells. Biochem. Biophys. Res. Commun. 2008;367:899–905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18194669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vallier L., Mendjan S., Brown S., Chng Z., Teo A., Smithers L.E., Trotter M.W.B.B., Cho C.H.H.H.-H., Martinez A., Rugg-Gunn P., et al.  Activin/Nodal signalling maintains pluripotency by controlling Nanog expression. Development. 2009;136:1339–1349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2687465</ArticleId>
            <ArticleId IdType="pubmed">19279133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang D.W., Lagace T.A., Garuti R., Zhao Z., McDonald M., Horton J.D., Cohen J.C., Hobbs H.H. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 2007;282:18602–18612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17452316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Zhou H., Su Y., Sun Z., Zhang H., Zhang L., Zhang Y., Ning Y., Chen Y.G., Meng A. Zebrafish Dpr2 inhibits mesoderm induction by promoting degradation of nodal receptors. Science. 2004;306:114–117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15459392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Z., Tuakli-Wosornu Y., Lagace T.A., Kinch L., Grishin N.V., Horton J.D., Cohen J.C., Hobbs H.H. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 2006;79:514–523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1559532</ArticleId>
            <ArticleId IdType="pubmed">16909389</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
